{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:12:28Z","timestamp":1790727148146,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013276","name":"Interreg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.lungcan.2020.08.020","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T11:06:49Z","timestamp":1599908809000},"page":"23-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression"],"prefix":"10.1016","volume":"149","author":[{"given":"Malene St\u00f8chkel","family":"Frank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe","family":"B\u00f8dtger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asbj\u00f8rn","family":"H\u00f8egholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Merete","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2020.08.020_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10147-018-1344-x","article-title":"Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice","volume":"24","author":"Hotta","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.020_bib0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.lungcan.2020.08.020_bib0015","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10066","key":"10.1016\/j.lungcan.2020.08.020_bib0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.lungcan.2020.08.020_bib0025","doi-asserted-by":"crossref","first-page":"32590","DOI":"10.3402\/ecrj.v3.32590","article-title":"Accuracy and consequences of same-day, invasive lung cancer workup - a retrospective study in patients treated with surgical resection","volume":"3","author":"Madsen","year":"2016","journal-title":"Eur. Clin. Respir. J."},{"issue":"3","key":"10.1016\/j.lungcan.2020.08.020_bib0030","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/LBR.0000000000000297","article-title":"Ultrasound-guided lung biopsy in the hands of respiratory physicians: diagnostic yield and complications in 215 consecutive patients in 3 centers","volume":"23","author":"Laursen","year":"2016","journal-title":"J. Bronchology Interv. Pulmonol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.08.020_bib0035","article-title":"Fluoroscopy guided percutaneous biopsy in combination with bronchoscopy and endobronchial ultrasound in the diagnosis of suspicious lung lesions - the triple approach","volume":"7","author":"Sidhu","year":"2020","journal-title":"Eur. Clin. Respir. J."},{"issue":"4","key":"10.1016\/j.lungcan.2020.08.020_bib0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000492578","article-title":"Endoscopic ultrasound with bronchoscope-guided fine needle aspiration for the diagnosis of paraesophageally located lung lesions","volume":"97","author":"Skovgaard Christiansen","year":"2019","journal-title":"Respiration"},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2020.08.020_bib0045","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2013-203618","article-title":"British Thoracic Society Guideline for Diagnostic Flexible Bronchoscopy in Adults: Accredited by NICE","volume":"68","author":"Du Rand","year":"2013","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.lungcan.2020.08.020_bib0050","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/PAI.0000000000000540","article-title":"Paired comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx","volume":"25","author":"Skov","year":"2017","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.08.020_bib0055","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/cas.12963","article-title":"Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure","volume":"107","author":"Kawamura","year":"2016","journal-title":"Cancer Sci."},{"issue":"50","key":"10.1016\/j.lungcan.2020.08.020_bib0060","doi-asserted-by":"crossref","first-page":"29525","DOI":"10.18632\/oncotarget.25705","article-title":"Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer","volume":"9","author":"Ichihara","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.lungcan.2020.08.020_bib0065","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/1759-7714.13035","article-title":"Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure","volume":"10","author":"Zhou","year":"2019","journal-title":"Thorac. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.020_bib0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lungcan.2014.08.016","article-title":"Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)","volume":"86","author":"Chouaid","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.08.020_bib0075","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1038\/srep20090","article-title":"Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer","volume":"6","author":"Sheng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2020.08.020_bib0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2016.07.013","article-title":"Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma","volume":"99","author":"Song","year":"2016","journal-title":"Lung Cancer (Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2020.08.020_bib0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2018.11.025","article-title":"Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion","volume":"127","author":"Sakai","year":"2019","journal-title":"Lung Cancer (Amsterdam, Netherlands"},{"issue":"3","key":"10.1016\/j.lungcan.2020.08.020_bib0090","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.4143\/crt.2018.537","article-title":"Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer","volume":"51","author":"Shin","year":"2019","journal-title":"Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.lungcan.2020.08.020_bib0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cllc.2019.05.013","article-title":"Adjuvant chemotherapy increases programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer recurrence","volume":"20","author":"Lacour","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2020.08.020_bib0100","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/cas.13072","article-title":"Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy","volume":"107","author":"Zhang","year":"2016","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.lungcan.2020.08.020_bib0105","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/j.cllc.2017.04.008","article-title":"Programmed death ligand 1 expression in paired non-small cell lung cancer tumor samples","volume":"18","author":"Cho","year":"2017","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2020.08.020_bib0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10555-011-9273-4","article-title":"Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy","volume":"30","author":"Kepp","year":"2011","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.lungcan.2020.08.020_bib0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2019.06.005","article-title":"Heterogeneity of PD-L1 expression in non-small cell lung cancer: implications for specimen sampling in predicting treatment response","volume":"134","author":"Haragan","year":"2019","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2020.08.020_bib0120","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.bbrc.2018.03.053","article-title":"Programmed death ligand 1 expression and CD8(+) tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer","volume":"498","author":"Zhou","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.lungcan.2020.08.020_bib0125","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1213934","article-title":"Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: implications for immunotherapy","volume":"5","author":"Pinato","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lungcan.2020.08.020_bib0130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2017.01.004","article-title":"Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas","volume":"75","author":"Kim","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"19","key":"10.1016\/j.lungcan.2020.08.020_bib0135","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2020.08.020_bib0140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10027","key":"10.1016\/j.lungcan.2020.08.020_bib0145","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"14","key":"10.1016\/j.lungcan.2020.08.020_bib0150","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2012positive, advanced non\u2012small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2020.08.020_bib0155","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtho.2018.04.039","article-title":"Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer","volume":"13","author":"Fehrenbacher","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl. 4","key":"10.1016\/j.lungcan.2020.08.020_bib0160","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.020_bib0165","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdy545","article-title":"Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial","volume":"30","author":"Herbst","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.020_bib0170","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2017.10.014","article-title":"The significance of the PD-L1 expression in non-small-cell lung cancer: trenchant double swords as predictive and prognostic markers","volume":"19","author":"Takada","year":"2018","journal-title":"Clin. Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:43:11Z","timestamp":1759236191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220305948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":34,"alternative-id":["S0169500220305948"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.020","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}